Benoxaprofen (Synonyms: LRCL 3794, NSC 299582) |
Catalog No.GC49836
One-Click Copy Product Info
|
Benoxaprofen (LRCL 3794) is a potent and long-acting anti-inflammatory and antipyretic compound.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51234-28-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Benoxaprofen is a non-steroidal anti-inflammatory drug.1 It inhibits prostaglandin E2 and leukotriene C4 production in isolated mouse peritoneal macrophages stimulated with A23187 when used at a concentration of 100 µM.2 Benoxaprofen (25 and 50 µg/ml) inhibits serum-induced chemotaxis of isolated rat peritoneal leukocytes.3 It induces hemolysis in isolated human erythrocytes and histamine release in isolated rat peritoneal mast cells in a light-dependent manner when used at a concentration of 10 µM.4 Benoxaprofen reduces carrageenan-induced paw edema and yeast-induced fever in rats and acetic acid-induced writhing in mice in a dose-dependent manner.1 Formulations containing benoxaprofen have previously been used in the treatment of osteoarthritis and rheumatoid arthritis.
1.Cashin, C.H., Dawson, W., and Kitchen, E.A.The pharmacology of benoxaprofen (2-[4-chlorophenyl]-α-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with antiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesisJ. Pharm. Pharmacol.29(6)330-336(1977) 2.Brune, K., Aehringhaus, U., and Peskar, B.A.Pharmacological control of leukotriene and prostaglandin production from mouse peritoneal macrophagesAgents Actions14(5-6)729-734(1984) 3.Meacock, S.C., and Kitchen, E.A.Effects of the non-steroidal anti-inflammatory drug benoxaprofen on leucocyte migrationJ. Pharm. Pharmacol.31(6)366-370(1979) 4.Sik, R.H., Paschall, C.S., and Chignell, C.F.The phototoxic effect of benoxaprofen and its analogs on human erythrocytes and rat peritoneal mast cellsPhotochem. Photobiol.38(4)411-415(1983)
| Cas No. | 51234-28-7 | SDF | |
| Synonyms | LRCL 3794, NSC 299582 | ||
| Canonical SMILES | O=C(C(C)C1=CC=C2OC(C3=CC=C(Cl)C=C3)=NC2=C1)O | ||
| Formula | C16H12ClNO3 | M.Wt | 301.7 |
| Solubility | N/A | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3146 mL | 16.5728 mL | 33.1455 mL |
| 5 mM | 662.9 μL | 3.3146 mL | 6.6291 mL |
| 10 mM | 331.5 μL | 1.6573 mL | 3.3146 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)